drugset / Trial / NCT03142256
3Ps for Prevention Study (Perception, Partners, Pills)
Phase 4
Unknown
200 enrolled
Desmond Tutu HIV Centre
Bill and Melinda Gates Foundation · collabNational Institute of Mental Health (NIMH) · collabUniversity of Washington · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This study has two phases. It will be conducted in one site in CT only. Phase I is to enumerate interest in PrEP uptake among young South African women exposed to a culturally-appropriate social marketing campaign. This enumeration will also serve as a recruitment strategy for a cohort with open-label PrEP access in Phase II. The cohort will assess PrEP acceptability and adherence among 200 HIV-uninfected young women who are offered open-label daily oral PrEP and randomized to receive or not receive a short term cash incentive conditional on study drug adherence.
Timeline
- Start
- 2017-03-24
- Primary completion
- 2019-06-30
- Completion
- 2019-06-30
Publications
- Celum CL, Gill K, Morton JF, Stein G, Myers L, Thomas KK, McConnell M, van der Straten A, Baeten JM, Duyver M, Mendel E, Naidoo K, Dallimore J, Wiesner L, Bekker LG. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. J Int AIDS Soc. 2020 Nov;23(11):e25636. doi: 10.1002/jia2.25636.
- Morton JF, Myers L, Gill K, Bekker LG, Stein G, Thomas KK, Duyver M, van der Straten A, McConnell M, Aunger R, Curtis V, de Witt Huberts J, Van Damme L, Baeten JM, Celum C. Evaluation of a behavior-centered design strategy for creating demand for oral PrEP among young women in Cape Town, South Africa. Gates Open Res. 2020 Jul 3;4:29. doi: 10.12688/gatesopenres.13103.2. eCollection 2020.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tenofovir | Small molecule | — | Oral |
Indications
No indication recorded.